{"id":"https://openalex.org/W2590592356","doi":null,"title":"Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients","display_name":"Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients","publication_year":2017,"publication_date":"2017-01-01","ids":{"openalex":"https://openalex.org/W2590592356","mag":"2590592356"},"language":"en","primary_location":{"id":"mag:2590592356","doi":null,"is_oa":false,"landing_page_url":"https://www.alliedacademies.org/articles/randomized-phase-ii-study-of-erlotinib-as-firstline-or-secondline-therapy-for-egfr-mutationpositive-advanced-lung-adenocarcinoma-p.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S90794122","display_name":"Biomedical Research-tokyo","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4322697010","host_organization_name":"Biomedical Research Foundation","host_organization_lineage":["https://openalex.org/P4322697010"],"host_organization_lineage_names":["Biomedical Research Foundation"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Biomedical Research-tokyo","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100409246","display_name":"Wei Zhao","orcid":"https://orcid.org/0000-0003-0578-4089","observed_orcids":["https://orcid.org/0000-0003-0578-4089"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wei Zhao","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-0578-4089","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100644710","display_name":"Xingchen Liu","orcid":"https://orcid.org/0000-0002-5638-4053","observed_orcids":["https://orcid.org/0000-0002-5638-4053"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xingchen Liu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5638-4053","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100627661","display_name":"Qing Tian","orcid":"https://orcid.org/0000-0003-2795-363X","observed_orcids":["https://orcid.org/0000-0003-2795-363X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qing Tian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074106391","display_name":"Yan Chang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yan Chang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044214094","display_name":"Zhen Yang","orcid":"https://orcid.org/0000-0002-2267-4589","observed_orcids":["https://orcid.org/0000-0002-2267-4589"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhen Yang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2267-4589","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5011268957","display_name":"Liangan Chen","orcid":"https://orcid.org/0000-0002-1829-3134","observed_orcids":["https://orcid.org/0000-0002-1829-3134"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Liangan Chen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1829-3134","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"4","first_page":"1917","last_page":"1921"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/egfr-mutation","display_name":"EGFR mutation","score":0.9649999737739563},{"id":"https://openalex.org/keywords/advanced-lung-adenocarcinoma","display_name":"advanced lung adenocarcinoma","score":0.8870000243186951},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9890000224113464},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8399999737739563},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9380000233650208},{"id":"https://openalex.org/keywords/cisplatin","display_name":"cisplatin","score":1.0},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8270000219345093},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.9819999933242798},{"id":"https://openalex.org/keywords/sequential-therapy","display_name":"sequential therapy","score":0.47600001096725464},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9639999866485596},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9750000238418579}],"concepts":[{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.9793674945831299},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.7739423513412476},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7429094314575195},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.7031784057617188},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6973772644996643},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6933815479278564},{"id":"https://openalex.org/C2909325608","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib Hydrochloride","level":5,"score":0.6136277914047241},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5578100085258484},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.5371435880661011},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.5361497402191162},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.5320566296577454},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.25942015647888184}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2590592356","doi":null,"is_oa":false,"landing_page_url":"https://www.alliedacademies.org/articles/randomized-phase-ii-study-of-erlotinib-as-firstline-or-secondline-therapy-for-egfr-mutationpositive-advanced-lung-adenocarcinoma-p.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S90794122","display_name":"Biomedical Research-tokyo","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4322697010","host_organization_name":"Biomedical Research Foundation","host_organization_lineage":["https://openalex.org/P4322697010"],"host_organization_lineage_names":["Biomedical Research Foundation"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Biomedical Research-tokyo","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1967394241","https://openalex.org/W1970476748","https://openalex.org/W1993020885","https://openalex.org/W2060299515","https://openalex.org/W2072299610","https://openalex.org/W2106787323","https://openalex.org/W2110900526","https://openalex.org/W2111662961","https://openalex.org/W2119002966","https://openalex.org/W2130256619","https://openalex.org/W2132157071","https://openalex.org/W2132870547","https://openalex.org/W2133149289","https://openalex.org/W2138297714","https://openalex.org/W2144180913","https://openalex.org/W2158134441","https://openalex.org/W2160336497","https://openalex.org/W2160982674","https://openalex.org/W2161821474","https://openalex.org/W2171139285"],"related_works":["https://openalex.org/W2111662961","https://openalex.org/W2129904284","https://openalex.org/W2241000884","https://openalex.org/W2074471209","https://openalex.org/W2328523564","https://openalex.org/W2144180913","https://openalex.org/W2416274847","https://openalex.org/W2131795655","https://openalex.org/W32726825","https://openalex.org/W2914693199"],"abstract_inverted_index":{"Epidermal":[0],"Growth":[1],"Factor":[2],"Receptor":[3],"(EGFR)":[4],"mutation":[5],"in":[6,14,19,69,112,131,154],"patients":[7,72,78],"with":[8,73],"Non-Small":[9],"Cell":[10],"Lung":[11],"Cancer":[12],"(NSCLC)":[13],"Asian":[15],"population":[16],"could":[17],"benefit":[18],"survival":[20],"to":[21,57,81],"Tyrosine":[22],"Kinase":[23],"Inhibitor":[24],"(TKI)":[25],"treatment.":[26],"Standard":[27],"chemotherapy":[28,145,147],"was":[29,95,102],"the":[30,109,132],"mainstay":[31],"for":[32],"advanced":[33,74],"NSCLC.":[34],"In":[35],"this":[36],"randomized,":[37],"single":[38],"center,":[39],"phase":[40],"2":[41],"studies,":[42],"we":[43],"investigated":[44],"erlotinib":[45,65,143,149],"as":[46,53,61,66],"first-line":[47,62],"therapy":[48,55,63,68],"plus":[49,64,144,148],"docetaxel":[50,58],"and":[51,59,87,99,115,121,146],"cisplatin":[52,60],"second-line":[54,67],"compared":[56],"treat":[70],"naive":[71],"lung":[75],"adenocarcinoma.":[76],"81":[77],"were":[79,118],"randomized":[80],"receive":[82],"erlotinib+chemotherapy":[83],"(E+C":[84],"group,":[85,90],"n=43)":[86],"chemotherapy+erlotinib":[88],"(C+E":[89],"n=38).":[91],"The":[92,106,126],"primary":[93],"objective":[94,101,103,127],"Overall":[96],"Survival":[97],"(OS)":[98],"secondary":[100],"response":[104,128],"rate.":[105],"data":[107],"showed":[108,152],"median":[110],"OS":[111],"E+C":[113],"group":[114,117],"C+E":[116],"23.7":[119],"months":[120],"24.2":[122],"months,":[123],"respectively":[124],"(p=0.652).":[125],"rate":[129],"differed":[130],"two":[133],"groups":[134],"(p<0.001).":[135],"Our":[136],"results":[137],"indicated":[138],"that":[139],"sequential":[140],"usage":[141],"of":[142],"did":[150],"not":[151],"difference":[153],"OS.":[155]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2017-03-03T00:00:00"}